Carillon Tower Advisers released its “Carillon Eagle Mid Cap Growth Fund” second-quarter 2025 investor letter, showcasing a strong rebound in mid-cap stocks. The Russell Midcap Growth Index outperformed the Russell Midcap Value Index in the quarter. Check the fund’s top 5 holdings for insights into its best picks for 2025.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) was highlighted in Carillon Eagle Mid Cap Growth Fund’s second-quarter 2025 investor letter. The biopharmaceutical company saw a one-month return of 11.69% and shares lost 86.53% over the last 52 weeks. On September 2, 2025, Sarepta Therapeutics closed at $18.16 per share with a market capitalization of $1.901 billion.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) reported quarterly revenue exceeding expectations but posted a larger than expected loss per share and revised its 2025 sales forecast downward. The stock faced a sharp sell-off after a patient died from acute liver failure after receiving its gene therapy, Elevidys, for Duchenne muscular dystrophy.

Read more at Yahoo Finance: Sarepta Therapeutics (SRPT) Fell Despite Reporting Good Results